Table 2.
Reason for B19 testing | No. of women (n = 72) | Parameter | IVb |
B19 DNA (IU/ml) | |
---|---|---|---|---|---|
IgG | IgM | ||||
Symptoms | 29 | Median | 4.10 | 5.65 | 2.14 × 104 |
Mean | 4.45 | 6.98 | 4.94 × 104 | ||
SD | 1.79 | 4.08 | 4.98 × 104 | ||
Suspected contacts | 12 | Median | 4.00 | 2.80 | 1.00 × 104 |
Mean | 4.62 | 3.01 | 1.79 × 104 | ||
SD | 1.19 | 1.93 | 2.24 × 104 | ||
Routine screening | 14 | Median | 3.90 | 1.70 | 5.19 × 102c |
Mean | 3.52 | 2.38 | 4.50 × 102 | ||
SD | 2.35 | 1.26 | 2.46 × 102 | ||
Abnormal US image | 17 | Median | 4.20 | 1.15 | 1.00 × 104 |
Mean | 4.20 | 1.32 | 1.99 × 109 | ||
SD | 1.90 | 0.71 | 5.25 × 109 |
The table reports median and mean values and standard deviations for B19 specific IgG and IgM IVs (index values) and DNA detected in serum samples from pregnant women that tested for B19 infection following the onset of B19-related symptoms or suspected contact with cases of erythema infectiosum during the course of a routine screening, or because fetal anomalies were observed during US examination, as indicated in column 1.
The median IgM IV for women with B19-related symptoms is statistically higher than in the other groups.
The median B19 viremia for women tested in the course of a routine screening is lower than in the other groups.